id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-354006-j1y42oxu	Ozdemir, Vural	Shifting emphasis from pharmacogenomics to theragnostics	2006		.txt	text/plain	4200	142	29	As biomarker applications move towards point-of-care to individualize drug therapy, a number of qualitatively different concerns arise relating to gene patents and ethical and therapeutic policy aspects of theragnostic testing 4, 8, 9 . In the present analyses, we 'unpack' and contrast the motivations at play that are driving the pursuit for theragnostic patents and its bioethical corollaries in: (1) fundamental upstream basic research oriented to the discovery of genes for human diseases; and (2) downstream clinical applications at point-of-care as theragnostic tests to stratify patient populations for individualization of pharmacotherapy. While genetic tests hold the promise of a more rational clinical forecast and management of disease risk in the future, they are also raising concerns about the provision of public healthcare services (reduced access) and the impact of market forces on the products of research (commercialization of technologies) and academic freedom.	./cache/cord-354006-j1y42oxu.txt	./txt/cord-354006-j1y42oxu.txt